Skip to main content
Top
Published in: Drug Safety 10/2007

01-10-2007 | Abstracts

Poster Presentations

Authors: O. Lefebvre, S. Mayall, K. Seamon, L. Mclean, A. Banerjee

Published in: Drug Safety | Issue 10/2007

Login to get access

Excerpt

Background: Following the successful experience of chemical generics and pushed by economic arguments for wider patient access to biological drugs, biosimilars are now coming onto the scene, with EMEA regulations currently taking shape and two initial hGH products approved in mid-2006. Despite significant enthusiasm and expectations, the question still remains to what extent they are clinically and commercially viable because of potential safety, manufacturing, regulatory and commercial risks. …
Metadata
Title
Poster Presentations
Authors
O. Lefebvre
S. Mayall
K. Seamon
L. Mclean
A. Banerjee
Publication date
01-10-2007
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 10/2007
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200730100-00058

Other articles of this Issue 10/2007

Drug Safety 10/2007 Go to the issue